Encompass Health Co. (NYSE:EHC - Free Report) - Leerink Partnrs increased their Q1 2025 earnings per share estimates for shares of Encompass Health in a research report issued on Tuesday, February 11th. Leerink Partnrs analyst W. Mayo now forecasts that the company will post earnings per share of $1.26 for the quarter, up from their previous estimate of $1.21. The consensus estimate for Encompass Health's current full-year earnings is $4.76 per share. Leerink Partnrs also issued estimates for Encompass Health's Q3 2025 earnings at $1.15 EPS, Q4 2025 earnings at $1.30 EPS, FY2025 earnings at $4.90 EPS, Q1 2026 earnings at $1.29 EPS, Q3 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.34 EPS and FY2026 earnings at $5.01 EPS.
Encompass Health (NYSE:EHC - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.17 EPS for the quarter, beating analysts' consensus estimates of $1.05 by $0.12. Encompass Health had a return on equity of 18.06% and a net margin of 8.48%.
A number of other equities analysts also recently issued reports on EHC. StockNews.com upgraded Encompass Health from a "hold" rating to a "buy" rating in a research note on Saturday. Truist Financial restated a "buy" rating and issued a $116.00 target price (up previously from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. Barclays boosted their target price on Encompass Health from $116.00 to $118.00 and gave the stock an "overweight" rating in a research note on Friday, February 7th. William Blair restated an "outperform" rating on shares of Encompass Health in a research note on Friday, February 7th. Finally, KeyCorp boosted their target price on Encompass Health from $117.00 to $120.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Encompass Health currently has an average rating of "Buy" and an average target price of $107.67.
Check Out Our Latest Stock Report on Encompass Health
Encompass Health Stock Up 0.8 %
EHC stock traded up $0.77 during mid-day trading on Wednesday, reaching $100.91. 588,630 shares of the company traded hands, compared to its average volume of 601,568. The stock has a market cap of $10.17 billion, a price-to-earnings ratio of 22.62, a P/E/G ratio of 1.18 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. Encompass Health has a fifty-two week low of $73.02 and a fifty-two week high of $104.55. The firm's 50 day moving average price is $95.97 and its 200 day moving average price is $95.52.
Institutional Investors Weigh In On Encompass Health
A number of hedge funds and other institutional investors have recently bought and sold shares of EHC. T. Rowe Price Investment Management Inc. bought a new stake in Encompass Health during the 4th quarter valued at $152,953,000. Norges Bank bought a new position in shares of Encompass Health in the fourth quarter worth $100,637,000. Raymond James Financial Inc. bought a new position in shares of Encompass Health in the fourth quarter worth $77,944,000. Point72 Asset Management L.P. increased its holdings in shares of Encompass Health by 2,458.5% in the third quarter. Point72 Asset Management L.P. now owns 869,104 shares of the company's stock worth $83,990,000 after purchasing an additional 835,135 shares during the period. Finally, Jennison Associates LLC bought a new position in shares of Encompass Health in the fourth quarter worth $52,094,000. Institutional investors own 97.25% of the company's stock.
Insider Activity at Encompass Health
In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total transaction of $495,578.18. Following the sale, the chief accounting officer now owns 69,164 shares of the company's stock, valued at $6,798,129.56. The trade was a 6.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.10% of the stock is owned by company insiders.
About Encompass Health
(
Get Free Report)
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
See Also
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
